Glura 100mg Tablet contains Sitagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin works by enhancing the levels of incretin hormones, which increase insulin synthesis and release from pancreatic beta cells in a glucose-dependent manner, while simultaneously decreasing glucagon secretion from pancreatic alpha cells. This dual action helps to regulate blood glucose levels effectively without causing significant hypoglycemia. Glura 100mg is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The recommended dose is 100 mg once daily, with or without food. It is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, though it is generally well tolerated. Renal function should be assessed prior to initiation and periodically thereafter, with dose adjustments made as necessary in patients with renal impairment. Glura 100mg offers a convenient and effective option for improving glycemic control and reducing the risk of diabetes-related complications.